Gradient Investments’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Gradient Investments’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-36	Closed	-$4K	–	1444
2022 Q1	$4K	Hold	36	–	–	﹤0.01%	952
2021 Q4	$4K	Buy	+36	New	+$3.93K	﹤0.01%	997
2017 Q1	–	Sell	-15,283	Closed	-$247K	–	854
2016 Q4	$247K	Sell	15,283 -604	-4%	-$11K	0.02%	172
2016 Q3	$288K	Buy	+15,887	New	+$310K	0.03%	164

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Gradient Investments's HZNP Position: Q2 2022 in Review

Gradient Investments sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 36 shares — an estimated $4K sold.

Gradient Investments first reported a position in HZNP in Q3 2016 and held it in 4 quarters. The position peaked at $288K in Q3 2016. 614 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

Gradient Investments reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Gradient Investments sold 36 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $4K.
Gradient Investments first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 4 quarters.
Gradient Investments's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $288K in Q3 2016.
614 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Gradient Investments's 13F filing for Q2 2022, filed 11 Jul 2022.